EBV AND HHV-8 IN HEMATOLOGY: UPDATE ON RELATED- LYMPHOPROLIFERATIVE DISORDERS AND VIRAL SEPSIS (SIE 2026) - Oct 6, 2026 - Abstract #MP05; "Adoptive immunotherapies, including tabelecleucel, are recommend- ed in relapsed/refractory PTLDs, following rituximab and rit- uximab with chemotherpay 7,8. In the SOT setting, serological screening/molecular surveillance and early use of rituximab and switch to mTor inhibitors are life-saving 10. The demarcation between KICS and HHV-8 related Hemophagocytic Lympho-Hystiocytosis (HLH) or EBV-HLH, may be blurred and serum cytokine pro- filing may help in the differential diagnosis among these cy- tokine storms 9,10."
Aplastic Anemia • Bone Marrow Transplantation • CNS Lymphoma • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Human Immunodeficiency Virus • Infectious Disease • Kaposi Sarcoma • Lymphoma • Rare Diseases • Sarcoma • Septic Shock • Solid Organ Transplantation • Solid Tumor
|
|
M. Luppi1; P. Barozzi1; P. Comoli2; A. Mularoni3
|